MDL 3094 Status Update
To view a copy of this licence, visit About this article Cite this article Hansen, H.H., Grnlund, R.V., Baader-Pagler, T
Quick Answer: Insomnia is not established as a common side effect of Wegovy based on clinical trial data, though some patients report sleep disturbances that may relate to metabolic changes, gastrointestinal discomfort, or the weight loss process itself rather than direct medication effects
This means you could avoid long wait times or multiple clinic visits
We do have: 10+ year safety data for earlier GLP-1 agonists (liraglutide, exenatide) Growing evidence of cardiovascular benefits from weight loss medications Understanding that obesity itself has well-documented health risks The risk-benefit calculation often favors treatment, but this is an individual decision that should be made with your healthcare provider based on your specific medical situation
A practical guide to using medicines to manage overweight and obesity